HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardioprotective properties of humoral factors released from rat hearts subject to ischemic preconditioning.

Abstract
Myocardial protection can be achieved by transfer of coronary effluent from ischemically preconditioned to non-preconditioned hearts. This study was designed to test the hypothesis that preconditioned effluent from rat hearts purified by Sep-Pak C-18 cartridges could induce remote cardioprotection against ischemia/reperfusion (I/R) injury through the activation of protein kinase C signaling pathway. Buffer-perfused rat hearts were subject to 30 min ischemia and 60 min reperfusion. The myocardial I/R injury was assessed by postischemic contractile function recovery and infarct size. The protective effect of coronary effluent collected during ischemic preconditioning (IPC) was tested in non-preconditioned hearts in presence or absence of a PKC inhibitor, chelerythrine. Infarct size was 17 +/- 2% in preconditioned versus 37 +/- 1% in control hearts (P < 0.001). Hearts perfused with fresh preconditioned effluent had infarct sizes of 16 +/- 3% versus 36 +/- 1% in hearts treated with non-preconditioned effluent. The cardioprotective effect was lost when the effluent was left at room temperature during 24 h (infarct size, 40 +/- 3%) or heated to 70 degrees C (26 +/- 4%, P < 0.05) or 100 degrees C (39 +/- 1%, P < 0.001). The lyophilized effluent was stable for 30 days, and its purification in a Sep-Pak C-18 column resulted in a hydrophobic fraction that reduced the infarct size to 17 +/- 2% versus 38 +/- 2% for the hydrophilic fraction. Chelerythrine (100 microM) inhibited the reduction of infarct size induced by IPC (35 +/- 4%) or hydrophobic fraction (37 +/- 3%). Recovery of the contractile function at reperfusion was higher in preconditioned group (74 +/- 6% versus 17 +/- 7% in control, P < 0.001) and hydrophobic fraction (66 +/- 7% versus 8 +/- 4% in hydrophilic fraction, P < 0.001). Similarly, chelerythrine was able to abrogate the contractile function recovery (12 +/- 6%, P < 0.001 versus preconditioned group and 19 +/- 7%, P < 0.001 versus hydrophobic fraction). In conclusion, the cardioprotective factors released in the coronary effluent by IPC are thermolabile hydrophobic substances with molecular weights higher than 3.5 kDa and acting through PKC activation.
AuthorsFredson Costa Serejo, Luiz Fernando Rodrigues Jr, Kelly Campos da Silva Tavares, Antonio Carlos Campos de Carvalho, Jose Hamilton Matheus Nascimento
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 49 Issue 4 Pg. 214-20 (Apr 2007) ISSN: 0160-2446 [Print] United States
PMID17438406 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Alkaloids
  • Benzophenanthridines
  • Cardiotonic Agents
  • Protein Kinase Inhibitors
  • Silicon Dioxide
  • octadecyl silane-bonded silica
  • chelerythrine
  • Protein Kinase C
Topics
  • Alkaloids (pharmacology)
  • Analysis of Variance
  • Animals
  • Benzophenanthridines (pharmacology)
  • Cardiotonic Agents (pharmacology)
  • Coronary Circulation (drug effects)
  • Coronary Vessels (physiopathology)
  • Disease Models, Animal
  • Heart Rate (drug effects)
  • Hot Temperature
  • Ischemic Preconditioning, Myocardial (methods)
  • Male
  • Myocardial Contraction (drug effects)
  • Myocardial Infarction (physiopathology, prevention & control)
  • Myocardial Reperfusion Injury (physiopathology, prevention & control)
  • Myocardium (metabolism)
  • Protein Kinase C (antagonists & inhibitors, metabolism)
  • Protein Kinase Inhibitors (pharmacology)
  • Rats
  • Rats, Wistar
  • Signal Transduction (drug effects)
  • Silicon Dioxide (pharmacology)
  • Ventricular Pressure (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: